Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Applied Genetic Tech (AGTC)

Applied Genetic Tech (AGTC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,747
  • Shares Outstanding, K 18,218
  • Annual Sales, $ 41,690 K
  • Annual Income, $ -2,010 K
  • 60-Month Beta 2.64
  • Price/Sales 1.38
  • Price/Cash Flow N/A
  • Price/Book 0.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.58
  • Number of Estimates 3
  • High Estimate -0.46
  • Low Estimate -0.64
  • Prior Year 0.07
  • Growth Rate Est. (year over year) -928.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.91 +6.53%
on 10/14/19
4.61 -32.75%
on 09/27/19
-0.58 (-15.76%)
since 09/13/19
3-Month
2.52 +23.02%
on 08/28/19
4.61 -32.75%
on 09/27/19
-0.57 (-15.53%)
since 07/12/19
52-Week
2.26 +37.17%
on 12/21/18
7.48 -58.56%
on 11/13/18
-3.53 (-53.24%)
since 10/12/18

Most Recent Stories

More News
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,...

AGTC : 3.10 (+1.31%)
OTIC : 2.23 (-0.45%)
Applied Genetic Technologies (AGTC) Reports Q4 Loss, Lags Revenue Estimates

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -13.73% and -42.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the...

AGTC : 3.10 (+1.31%)
Applied Genetic Technologies: Fiscal 4Q Earnings Snapshot

ALACHUA, Fla. (AP) _ Applied Genetic Technologies Corp. (AGTC) on Thursday reported a loss of $10.5 million in its fiscal fourth quarter.

AGTC : 3.10 (+1.31%)
Applied Genetic Technologies Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / September 26, 2019 / Applied Genetic Technologies Corp. (NASDAQ: ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on September 26,...

AGTC : 3.10 (+1.31%)
AGTC to Present at Upcoming Conferences

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,...

AGTC : 3.10 (+1.31%)
Analysts Estimate Applied Genetic Technologies (AGTC) to Report a Decline in Earnings: What to Look Out for

Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AGTC : 3.10 (+1.31%)
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 26, 2019

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,...

AGTC : 3.10 (+1.31%)
Analysts Estimate Applied Genetic Technologies (AGTC) to Report a Decline in Earnings: What to Look Out for

Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AGTC : 3.10 (+1.31%)
AGTC to Present at Upcoming Conferences

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,...

WFC : 49.27 (+0.12%)
AGTC : 3.10 (+1.31%)
American Gilsonite to Announce 2nd Quarter 2019 Financial Results

American Gilsonite Company (the "Company" or "AGC"), the world's principal commercial miner and processor of uintaite, the unique mineral marketed under its trademark name "Gilsonite," today announced...

AGTC : 3.10 (+1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AGTC with:

Business Summary

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis...

See More

Key Turning Points

2nd Resistance Point 3.29
1st Resistance Point 3.18
Last Price 3.10
1st Support Level 3.00
2nd Support Level 2.93

See More

52-Week High 7.48
Fibonacci 61.8% 5.49
Fibonacci 50% 4.87
Fibonacci 38.2% 4.25
Last Price 3.10
52-Week Low 2.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar